Studies on the serological markers for hepatitis B virus infection among type 2 diabetic patients by Ndako, James A. et al.




Received:	5	May	2020  |  Revised:	10	June	2020  |  Accepted:	11	June	2020
DOI: 10.1002/jcla.23464  
R E S E A R C H  A R T I C L E
Studies on the serological markers for hepatitis B virus 
infection among type 2 diabetic patients
James A. Ndako1  |   Obinna O. Nwankiti2 |   Joy O. Olorundare1 |   Stephen K.S. Ojo3 |   
Charles E. Okolie1 |   Oludolapo Olatinsu1 |   Victor T. Dojumo4
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.  



























were used to obtain relevant information and demographic data.
Result: Overall	 prevalence	 of	HBV	 infection	 among	 diabetes	 patients	was	 13.3%.	
Breakdown	showed	9	(5.0%)	seropositivity	was	obtained	among	male	subjects	com-
pared	 to	15(8.3%)	 recorded	among	 the	 females,	P =	 .834;	P <	 .05.	 Subjects	 aged	
41-50	years	recorded,	7(3.9%)	positivity	P =	.774;	P >	.05.	Educational	status	of	par-
ticipants	showed	22	(12.2%)	positivity	among	subjects	with	tertiary	level	of	educa-
tion P = .032; P <	 .05).	 Risk	 factors	 considered	 showed	 that	 5(2.8%).seropositive	
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1  | BACKGROUND
Hepatitis	B	virus	 (HBV)	 is	one	of	 the	most	common	chronic	 infec-
tions worldwide and the leading cause for hepatocellular carcinoma 
(HCC)	worldwide.1	 Based	on	WHO	 report,	 one-third	 of	 the	world	
population	estimated	at	about	2	billion	individuals	are	HBV-infected,	
including studies showing that about 240 million individuals are 
chronic carriers.2 Transmission of this virus occurs via exchange 
of	 bodily	 fluid	 such	 as	 blood,	 semen,	 and	 perinatal	 transmission.	
Hepatitis	B	has	been	majorly	associated	with	hepatocellular	 carci-
noma,	cirrhosis,	and	chronic	hepatitis,	and	this	makes	it	identifiable	
as a major health issue in various developing countries.3	An	increased	
rate	of	this	disease	occurrence	has	been	recorded	in	regions	like	East	
Asia	and	sub-Saharan	Africa	where	5%-10%	of	adults	in	these	loca-









be present in patient's serum.7 This surface antigen is present on the 
outer envelope alongside an inner nucleocapsid consisting of hepati-
tis	B	core	antigen	(HBcAg).8
Diagnosis of this virus is done by blood screening for the sur-




is	 serology,	 a	 term	 comprising	 the	 detection	 and	 quantification	
of	 viral	 antigens	 and	 viral	 specific	 antibodies,	 and	 the	 second	 is	
nucleic	acid	testing	(NAT)	for	the	detection	and	quantification	of	
HBV	genome	and	its	RNA	transcripts.9 The spread of this virus is 
rapidly on the increase globally; as large numbers of individuals are 
unaware of the ravaging effect of this virus nether do they know 
their status mostly in identified endemic regions. Complications 
can occur after prolonged infection with this virus and due to its 
asymptomatic nature. Transmission of the virus can easily occur 
without	adequate	precaution..10
Based	 on	 the	 increasing	 prevalence	 of	 HBV,	 various	 studies	
have been carried out on this virus with less information on its 
association	with	diabetic	patients.	HBV	outbreaks	have	been	ob-
served among diabetics in healthcare facilities and nursing homes. 





to their defective levels of T lymphocytes are vulnerable to viral 
infections as a result of an immune compromised system.
2  | METHOD
2.1 | Study area and population
The	study	was	conducted	at	the	Federal	Teaching	Hospital	Ido-Ekiti	
which is a tertiary health institution. The study population com-
prised of randomly selected confirmed diabetic patients attending 
the	outpatient	department	of	the	Teaching	Hospital.
2.2 | Ethical permit and consent
A	 proposal	 of	 the	 project	 was	 submitted	 to	 the	 Ethical	 Review	
Committee	of	the	Federal	Teaching	Hospital	 Ido-Ekiti,	where	ethi-
cal permit was sought for and obtained with protocol number: 
ERC/2018/02/27/103B.
2.3 | Inclusion and exclusion criteria
Individuals confirmed for type 2 diabetes mellitus diabetes were re-
cruited for the study. Persons who showed no interest in the study 
and are not diabetic were excluded from the study.




tionnaires were used to collect demographic data and other perti-
nent information.
2.5 | Sample collection and processing
Aseptic	collection	of	three	to	five	(3-5)	mL	of	blood	from	each	dia-
betic	patient	was	done.	At	room	temperature,	blood	samples	were	





procedures were strictly adhered to during the assaying process.
2.6 | Sample processing
Sera	 samples	 obtained	 were	 screened	 for	 HCV	 antibodies	 using	
ELISA	technique	according	to	the	manufactures	manual.	The	5	panel	
kit—rapid	 diagnostic	 test,	 was	 used	 to	 assay	 for	 serological	mark-
ers	 serum	 ALT	was	 also	 assayed	 for,	 according	 to	 manufacturer's	
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One-hundred	 (100)	 non-diabetics	 (Controls)	 subjects	 screened	
comprise	of	48	males	and	52	female,	with	a	record	of	4%	positivity	
for	the	male	control	subjects	as	compared	to	5%	positivity	recorded	
among	the	female	subjects,	P =	.739;	P > .05.
From	 the	 24	 positive	 samples,	 9	 (5.0%)	 males	 tested	 positive	
compared	to	15	(8.3%)	positivity	among	the	female	diabetic	subjects	






17	 (85.0%)	 tested	negative	while	 3	 (15.0%)	 tested	positive.	 In	 the	
age	 group	 between	 31	 and	 40	 years,	 a	 total	 of	 37	 (20.6%)	 were	
tested	and	32	(86.5%)	were	negative	while	5	(13.5%)	were	positive.	
Between	age	group	41	and	50,	 a	 total	of	40	 (22.2%)	were	 tested,	
having	7	(17.5%)	individuals	positive	and	33	(82.5%)	negative.	In	the	
age	range	51-60,	24	(13.3%)	individuals	were	tested	and	22	(991.7%)	




screened	out	of	which	22	 (12.2%)	 tested	positive	while	108	 (60.0%)	
tested	 negative.	 Among	 the	 41	 (22.8%)	 single	 subjects	 screened,	 2	
(1.1%)	tested	positive	while	39(21.7%)	were	negative	(Table	4).
The	result	based	on	educational	status	of	subjects	screened,	the	








among	 industrial	 workers,	 and	 1	 (0.6%)	 prevalence	 was	 recorded	












kit,	 showed	 that	 37.5%	 positivity	 was	 recorded	 among	 individu-
als	with	HBsAg,	and	8.3%	was	 recorded	 for	 subjects	with	HBsAb.	




HBsAg	 positivity	 was	 more	 prevalent	 among	 diabetic	 patients	
(13.3%),	compared	to	the	non-diabetic	subjects	(9%).	Although	this	
difference	 was	 statistically	 insignificant,	 it	 was	 of	 clinical	 impor-
tance. The result obtained from the sera samples screened among 
diabetic	patients	 showed	a	prevalence	 rate	of	13.3%.This	 result	 is	
comparable	 to	 the	 study	 carried	 out	 at	 Ahmadu	 Bello	 University,	
Zaria	 among	 diabetes	 where	 HBV	 prevalence	 of	 12.5%	 was	 re-
corded.12 Our findings also correspond with a national survey car-
ried	out	in	Nigeria	where	the	prevalence	of	12.2%	was	recorded.13 
A	study	done	in	Taiwan	also	showed	a	related	prevalence	of	13.5%	
among diabetic patients.14	However,	 the	 result	obtained	 from	 this	




Total Number of Respondents 
examined (%)
Number of Positive 
Respondents (%)
Number of Negative 
Respondents (%)
Male 71	(39.4%) 9	(5.0%) 62	(34.4%)
Female 109	(60.6%) 15	(8.3%) 94	(52.2%)
Total 180	(100%) 24	(13.3%) 156	(86.6%)
Note: P =	.834;	P < .05.
TA B L E  1  Distribution	of	HBV	among	
diabetics based on gender
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The	 distribution	 of	 HBV	 among	 male	 and	 female	 gender	 re-
corded	5.0%	and	8.3%	prevalence,	respectively,	statistical	analysis	
carried	 out	 showed	 that	HBV	 infection	 is	 not	 dependent	 on	 gen-









Considering	 age	 of	 subjects	 screened,	 a	 higher	 prevalence	 of	
3.9%	was	recorded	among	subjects	aged	41-50	years	compared	to	
the other age groups. The result obtained in this study is in contrast 
to a similar study in turn contradicts the outcome of studies con-
ducted	by	Mohd	et	 al	 (2013),	which	 reported	 a	higher	prevalence	
among	subjects	aged	25-34	years.20	A	similar	study	conducted	by	
Malewe	 et	 al	 (2017)	 at	 Lome	 showed	 a	 higher	 prevalence	 rate	 of	
21.67%	among	individuals	within	the	age	range	of	30-39.	However,	
results obtained in this study among the various age groups screened 
does not show any statistically significant =	0.774;	P >	.05	(Table	3).
Marital status has been observed to be a major determining 
factor	 in	the	occurrence	of	HBV	infection.	Studies	conducted	by	
Abdollahi	et	al	(2006)	showed	a	higher	prevalence	among	unmar-
ried subjects compared to those married.21	Interestingly,	this	work	
showed	a	higher	prevalence	of	12.2%	among	the	married	subjects	
compared to subjects of other marital status. These differences 
can be attributed to probable cultural diversities in such commu-
nities.	McQuillan	et	al	(1998)	also	recorded	a	significant	incidence	








Male 48 4	(4%) 44	(44%)
Female 52 5	(5%) 47	(47%)
Total 100 9	(9%) 91	(91%)
Note: P =	.739;	P > .05.
Age Category
Total Number of 
Respondents examined (%)
Number of Positive 
Respondents (%)
Number of Negative 
Respondents (%)
Below	20 20	(11.1%) 1	(0.6%) 19	(10.6%)
21-30 20	(11.1%) 3	(1.7%) 17	(9.4%)
31-40 37	(20.6%) 5	(2.8%) 32	(17.8%)
41-50 40	(22.2%) 7	(3.9%) 33	(18.3%)
51-60 24	(13.3%) 2	(1.1%) 22	(12.2%)
Above	60 39	(21.7%) 6	(3.3%) 33	(18.3%)
Total 180	(100%) 24	(13.4%) 156	(86.6%)
Note: P =	.774;	P > .05.
TA B L E  3  Distribution	of	HBV	among	
diabetics	based	on	Age
Marital Status
Number of Positive 
Respondents (%)
Number of Negative 
Respondents (%)
Total Number of 
Respondents (%)
Single 2	(1.1%) 39	(21.7%) 41	(22.8%)
Married 22	(12.2%) 108	(60.0%) 130	(72.2%)
Divorced 0	(0.0%) 9	(5.0%) 9	(5.0%)
Total 24	(13.3%) 156	(86.7%) 180	(100%)
Note: P =	.068;	P < .05.
TA B L E  4  Distribution	of	HBV	among	
diabetics	Based	on	Marital	status
Qualification
Total Number of 
Respondents examined (%)
Number of Positive 
Respondents (%)
Number of Positive 
Respondents (%)
Primary 6	(3.3%) 2	(1.1%) 4	(2.2%)
Secondary 25	(13.9%) 3	(1.7%) 22	(12.2%)
Tertiary 148	(82.2%) 18	(10.0%) 130	(72.2%)
No	Education 1	(0.5%) 1	(0.5%) 0	(0.0%)
Total 180	(100%) 24	(13.3%) 156	(86.7%)
Note: P = .032; P < .05.
TA B L E  5  Distribution	of	HBV	
among	diabetics	Based	on	Educational	
qualification
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rate among widows than individuals of other marital status22,23 
(Table	 4).	 This	 could	 be	 as	 a	 result	 of	 the	 sexual	 promiscuity	 of	
any of the partners. The rate of transmission of this virus among 
diabetic sexual partners can be reduced via the introduction of 
HBV	 vaccines,	 use	 of	 contraceptives,	 and	 public	 enlightenment	
campaign to educate the populace on preventive measures against 
the	HBV	infection.
The result based on educational status of subjects screened the 







is	 not	 much	 disseminated,	 although	 public	 health	 policies	 recom-
mend vaccination through educational campaigns to patients and 
public health professionals.
Based	 on	 the	 demographic	 factors,	 a	 prevalence	 of	 9	 (5.0%)	
was	 recorded	 among	 subjects	 who	 engaged	 in	 trading,	 while	 11	
(6.1%)	prevalence	rate	was	recorded	among	civil	workers,	3	 (1.7%)	
prevalence	among	industrial	workers,	and	1	(0.6%)	prevalence	was	
recorded	 among	 subjects	 who	 were	 students,.(P = value: .240; 
P >	 .05),	 (Table	 6).	 Though	 not	 statistically	 significant,	 risk	 factor	
studied shows a high prevalence among subjects with history of un-
safe	 social	practices,	with	a	prevalence	of	5	 (2.8%)	among	alcohol	
consumers.	This	 result	 is	 similar	 to	 the	study	of	Tekin	et	al	 (2015)	
showing	 an	HBV	 incidence	 rate	 of	 16.3%	 among	 alcohol	 consum-
ers employed for a study in Turkey.24	Based	on	the	clinical	history	
of	 infected	 individuals,	1.1%	prevalence	 rate	was	 recorded	among	
individuals with family history of hepatitis infection. The suscepti-
bility of such individuals may be linked to a hereditary factor in exis-
tence.25	The	association	between	HBV	infection	and	DM	is	related	
to	 the	direct	effects	of	HBV	on	pancreatic	 lymphocytes,	 resulting	
in	 decreased	 insulin	 production,	 while	 patients	 with	 HBV-protein	
X reduce the expression of insulin receptor proteins among such 
subjects.14
Considering	 the	 seromarkers	 for	 HBV	 infection	 from	 this	
study,	 the	highest	 rate	of	 positivity	 recorded	 involved	 the	HBcAb	
with	 54.2%	 among	 the	 diabetic	 subjects	 screened.	 According	 to	
Rehermann,26 patients with resolved infection have persistence of 
anti-HBc	for	life,	although	the	total	anti-HBc	is	predominantly	con-
sisting of IgG at about four to 6 months following the appearance 
of	 anti-HBc.	 However,	 hepatitis	 B	 core	 antibody	 (anti-HBc)	 is	 the	
Occupation
Total Number of 
Respondents (%)
Number of Positive 
Respondents (%)
Number of Negative 
Respondents (%)
Trading 64	(35.6%) 9	(5.0%) 55	(30.6%)
Civil	Servant 64	(35.5%) 11	(6.1%) 53	(29.4%)
Industry 18	(10.0%) 3	(1.7%) 15	(8.3%)
Student 34	(18.9%) 1	(0.6%) 33	(18.3%)
Total 180	(100%) 24	(13.4%) 156	(86.6%)
Note: P = .240; P > .05.
TA B L E  6  Distribution	of	HBV	
among	diabetics	Based	on	Occupational	
distribution of subjects screened
TA B L E  7  Distribution	of	HBV	among	diabetics	based	on	Risk	factors	examined
Risk Factor Response
Number of Positive 
Respondents
Number of Negative 
Respondents
Total Number of 
Respondents Examined Chi-Square
Alcohol	Consumption Yes 5	(2.8%) 32	(17.8%) 37	(20.6%) 0.001
No 19	(10.5%) 124	(68.9%) 143	(79.4%) df = 1
Total 24	(13.3%) 156	(86.7%) 180	(100.0%) P value =	.9711
Tribal Marks and Tattoos Yes 3	(1.7%) 16	(8.9%) 19	(10.6%) 0.111
No 21	(11.6%) 140	(77.8%) 161	(89.4%) df = 1
Total 24	(13.3%) 156	(86.7%) 180	(100.0%) P value =	.7391
Engage	in	Risky	
Behaviors
Yes 1	(0.6%) 21	(11.6%) 22	(12.2%) 1.675
No 23	(12.8%) 135	(75.0%) 158	(87.8) df = 1
Total 24	(13.3%) 156	(86.7%) 180	(100.0%) P value =	.1956
Sharing	of	Razor	Blade/
Scissors/Nail	cutter
Yes 3	(1.7%) 53	(29.4%) 56	(31.1%) 4.475
No 21	(11.6%) 103	(57.3%) 124	(68.9%) df = 1
Total 24	(13.3%) 156	(86.7%) 180	(100.0%) P value = .0344
Non-spousal	Sexual	
Intercourse	in	3-5	y
Yes 1	(0.6%) 6	(3.3%) 7	(3.9%) 0.006
No 23	(12.8%) 150	(83.3%) 173	(96.1%) 1
Total 24	(13.4%) 156	(86.6%) 180	(100.0%) P value =	.9397
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TA B L E  8  Distribution	of	HBV	among	diabetics	based	on	Clinical	History
Medical History Response
Total Number of Respondents 
Examined (%)
Number of Positive 
Respondents (%)




Yes 32	(17.8%) 5	(2.8%) 27	(15.0%) 0.177
No 148	(82.2%) 19	(10.5%) 129	(71.7%) df = 1
Total 180	(100.0%) 24	(13.3%) 156	(86.7%) P value =	.6741
Previous Record of 
Hepatitis	Virus
Yes 7	(3.9%) 2	(1.1%) 5	(2.8%) 0.000
No 173	(96.1%) 22	(12.2%) 151	(83.9%) df = 1
Total 180	(100.0%) 24	(13.3%) 156	(86.7%) P value = 1.000
Received	Blood	
Transfusion in Time 
Past
Yes 13	(7.2%) 0	(0.0%) 13	(7.2%) 0.791
No 167	(92.7%) 24	(13.3%) 143	(79.4%) 1
Total 180	(100.0%) 24	(13.3%) 156	(86.6%) P value =	.3737
Blood	Donation Yes 13	(7.2%) 0	(0.0%) 13	(7.2%) 2.156
No 167	(92.7%) 24	(13.3%) 143	(79.4%) df = 1




Yes 38	(21.1%) 4	(2.2%) 34	(18.9%) 0.328
No 142	(78.9%) 20	(11.1%) 122	(67.8%) df = 1
Total 180	(100.0%) 24	(13.3%) 156	(86.7%) P value = .5666
TA B L E  9  Overall	prevalence	of	HBV	markers	among	seropositive	subjects
S/N AGE SEX
OD 
value HBsAg HbsAb HbeAg HbeAb HBcAb
1 42 F 1.03 Negative Negative Negative Negative Negative
2 52 M 16.92 Positive Negative Negative Positive Positive
3 75 M 1.45 Negative Negative Negative Negative Negative
4 59 F 1.29 Negative Negative Negative Negative Negative
5 34 F 6.41 Positive Negative Negative Weakly Positive Positive
6 76 F 1.10 Negative Negative Negative Negative Negative
7 68 F 5.91 Negative Negative Negative Negative Positive
8 62 F 5.64 Negative Negative Positive Negative Negative
9 30 F 17.02 Positive Negative Negative Positive Positive
10 40 F 8.68 Positive Negative Negative Positive Positive
11 38 F 1.15 Negative Positive Negative Negative Negative
12 48 M 1.15 Negative Negative Negative Negative Positive
13 45 M 1.03 Negative Negative Negative Negative Negative
14 30 F 26.67 Positive Negative Negative Positive Positive
15 30 F 14.88 Positive Negative Negative Positive Positive
16 101 F 26.67 Positive Negative Negative Positive Positive
17 41 M 1.09 Negative Negative Negative Negative Negative
18 50 M 1.06 Negative Negative Negative Negative Positive
19 67 M 1.14 Negative Weakly Positive Negative Negative Positive
20 41 F 1.13 Negative Negative Negative Negative Negative
21 40 M 16.93 Positive Negative Negative Positive Positive
22 19 F 2.03 Negative Negative Negative Positive Negative
23 44 F 1.17 Negative Negative Negative Positive Negative
24 35 M 13.7 Positive Negative Negative Positive Positive
Abbreviations:	F,	Female;	M,	Male;	OD	value,	optical	density	value.
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Anti-HBe	 positivity	 showed	 a	 record	 of	 45.8%,	 in	 the	 natural	
history	 of	HBV	 infection,	 the	most	 important	 event	 is	HBeAg	 se-
roconversion	characterized	by	 loss	of	HBeAg	and	development	of	
antibody	 to	 HBeAg	 (anti-HBe).	 This	 generally	 occurs	 years	 after	
replicative	phase	and	indicates	a	transition	to	a	low/non-replicative	
phase with a potential for resolution of infection and improvement 
of	necro-inflammation	in	the	liver.28
The	 anti-HBs	 recorded	 8.3%	 positivity.	 According	 to	 Lee,29 
chronic	infection	is	indicated	in	the	occurrence	of	HBsAg	for	a	pe-
riod of 6 months or more after an acute infection. Chronic infection 











els of hepatic aminotransferase levels.29 Zhang et al30 in his studies 
recorded	1.6%	HBeAg	positivity	among	young	adults,	while	the	rate	
of positivity decreased with age due to the spontaneous seroconver-
sion	to	the	antibody	against	the	HBeAg	(Anti-HBe).
Anti-HBs	 which	 indicate	 antibody	 to	 the	 HBsAg	 showed	 35	
(17.5%)	positivity	among	children,	20.0%	among	young	adults,	11.6%	
among	 pregnant	 women,	 5.0%	 among	 blood	 donors,	 and	 14.5%	
among	apparently	healthy	subjects.	While	anti-HBs	recorded	18.7%	
positivity	among	subjects	aged	15-19	years	followed	by	11.7%	pos-





The	 presence	 of	 anti-HBs	 following	 acute	 infection	 generally	
indicates	 recovery	 and	 protective\immunity	 against	 re-infection.	
In	 addition,	 patients	 with	 resolution	 of	 infection	 have	 disappear-
ance	of	HBeAg	and	development	of	antibodies	to	hepatitis	B	e	an-
tigen	 (anti-HBe).	Patients	with	 resolved	 infection	have	persistence	
of	anti-HBc	for	life,	but	about	4-6	months	after	the	appearance	of	










the onset of T2DM recorded no significance statistical differ-
ence compared to risk factors among patients without the T2DM. 
However,	 individuals	 infected	 with	 T2DM	 had	 a	 higher	 incidence	
rate	of	HBV	 in	all	 the	age	 ranges	studied	when	compared	 to	non-




as vaccination and public health education to enlighten the populace 
on the scourge of this infectious agent coupled with improved diag-
nosis	for	early	detection	of	HBV	infection	among	diabetic	patients	
is	strongly	recommended,	for	policy	making	and	implementation	in	
such communities. This is to reduce to the barest minimum further 
complications among similar subjects in the population.
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